DLB
MCID: DMN031
MIFTS: 66

Dementia, Lewy Body (DLB)

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Mental diseases

Aliases & Classifications for Dementia, Lewy Body

MalaCards integrated aliases for Dementia, Lewy Body:

Name: Dementia, Lewy Body 57 25 13
Lewy Body Dementia 57 12 53 25 54 75 37 29 6 15 40
Lewy Body Disease 12 53 25 55 43 44 73
Diffuse Lewy Body Disease 57 12 53 25 75
Dementia with Lewy Bodies 12 76 25 54
Dlb 57 53 25 75
Autosomal Dominant Diffuse Lewy Body Disease 53 73
Diffuse Lewy Body Disease with Gaze Palsy 75
Lewy Body Variant of Alzheimer Disease 75
Dementia, Lewy Body, Susceptibility to 6
Lewy Body Dementia, Susceptibility to 57
Senile Dementia of the Lewy Body Type 12
Dementia of the Lewy Body Type 25
Lewy Body Type Senile Dementia 75
Dysphasic Dementia Hereditary 75
Cortical Lewy Body Disease 75
Dementia Lewy Body 75
Lewy Bodies 29
Lbd 25

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant

Miscellaneous:
onset in the sixth or seventh decades
phenotypic overlap with parkinson disease
allelic disorder to parkinson disease-1 (park1, )


HPO:

32
dementia, lewy body:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 127750
Disease Ontology 12 DOID:12217
ICD10 33 G31.83
ICD9CM 35 331.82
MeSH 44 D020961
NCIt 50 C84826
KEGG 37 H00066

Summaries for Dementia, Lewy Body

NINDS : 54 Dementia with Lewy bodies (DLB) is one of the most common types of progressive dementia. The central features of DLB include progressive cognitive decline, “fluctuations” in alertness and attention, visual hallucinations, and parkinsonian motor symptoms, such as slowness of movement, difficulty walking, or rigidity.  People may also suffer from depression.  The symptoms of DLB are caused by the build-up of Lewy bodies – accumulated bits of alpha-synuclein protein -- inside the nuclei of neurons in areas of the brain that control particular aspects of memory and motor control.  Researchers don’t know exactly why alpha-synuclein accumulates into Lewy bodies or how Lewy bodies cause the symptoms of DLB, but they do know that alpha-synuclein accumulation is also linked to Parkinson's disease, multiple system atrophy, and several other disorders, which are referred to as the "synucleinopathies." The similarity of symptoms between DLB and Parkinson’s disease, and between DLB and Alzheimer’s disease, can often make it difficult for a doctor to make a definitive diagnosis. In addition, Lewy bodies are often also found in the brains of people with Parkinson's and Alzheimer’s diseases.  These findings suggest that either DLB is related to these other causes of dementia or that an individual can have both diseases at the same time.  DLB usually occurs sporadically, in people with no known family history of the disease. However, rare familial cases have occasionally been reported.

MalaCards based summary : Dementia, Lewy Body, also known as lewy body dementia, is related to parkinson disease 3, autosomal dominant and corticobasal degeneration, and has symptoms including back pain, headache and pain. An important gene associated with Dementia, Lewy Body is SNCA (Synuclein Alpha), and among its related pathways/superpathways are Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Armodafinil and Modafinil have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and eye, and related phenotypes are dementia and parkinsonism

OMIM : 57 Dementia with Lewy bodies (DLB) is a neurodegenerative disorder clinically characterized by dementia and parkinsonism, often with fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Pathologically, Lewy bodies are present in a pattern more widespread than usually observed in Parkinson disease (see PD; 168600). Alzheimer disease (AD; 104300)-associated pathology and spongiform changes may also be seen (McKeith et al., 1996; Mizutani, 2000; McKeith et al., 2005). (127750)

UniProtKB/Swiss-Prot : 75 Dementia Lewy body: A neurodegenerative disorder characterized by mental impairment leading to dementia, parkinsonism, fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Brainstem or cortical intraneuronal accumulations of aggregated proteins (Lewy bodies) are the only essential pathologic features. Patients may also have hippocampal and neocortical senile plaques, sometimes in sufficient number to fulfill the diagnostic criteria for Alzheimer disease.

NIH Rare Diseases : 53 Lewy body dementia is one of the most common forms of progressive dementia. People affected by this condition may experience a variety of symptoms such as changes in alertness and attention; hallucinations; problems with movement and posture; muscle stiffness; confusion; and/or memory loss. Although the exact cause of Lewy body dementia is poorly understood, symptoms are thought to result when clumps of a protein called alpha-synuclein ("Lewy bodies") accumulate in the brain. Lewy body dementia usually occurs sporadically in people with no family history of the condition. Rarely, more than one family member may be affected. There is currently no cure for Lewy body dementia; however, medications may be available to help manage the associated symptoms.

MedlinePlus : 43 Lewy body disease is one of the most common causes of dementia in the elderly. Dementia is the loss of mental functions severe enough to affect normal activities and relationships. Lewy body disease happens when abnormal structures, called Lewy bodies, build up in areas of the brain. The disease may cause a wide range of symptoms, including Changes in alertness and attention Hallucinations Problems with movement and posture Muscle stiffness Confusion Loss of memory Lewy body disease can be hard to diagnose, because Parkinson's disease and Alzheimer's disease cause similar symptoms. Scientists think that Lewy body disease might be related to these diseases, or that they sometimes happen together. Lewy body disease usually begins between the ages of 50 and 85. The disease gets worse over time. There is no cure. Treatment focuses on drugs to help symptoms. NIH: National Institute of Neurological Disorders and Stroke

Genetics Home Reference : 25 Dementia with Lewy bodies is a nervous system disorder characterized by a decline in intellectual function (dementia), a group of movement problems known as parkinsonism, visual hallucinations, sudden changes (fluctuations) in behavior and intellectual ability, and acting out dreams while asleep (REM sleep behavior disorder). This condition typically affects older adults, most often developing between ages 50 and 85. The life expectancy of individuals with dementia with Lewy bodies varies; people typically survive about 5 to 7 years after they are diagnosed.

Disease Ontology : 12 A dementia and a synucleinopathy that is characterized by the development of abnormal proteinaceous (alpha-synuclein) cytoplasmic inclusions, called Lewy bodies, throughout the brain that results in progressive decline in mental abilities.

Wikipedia : 76 Dementia with Lewy bodies (DLB) is a type of dementia accompanied by changes in behavior, cognition and... more...

Related Diseases for Dementia, Lewy Body

Diseases related to Dementia, Lewy Body via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Related Disease Score Top Affiliating Genes
1 parkinson disease 3, autosomal dominant 32.8 LRRK2 MAPT PARK7 PRKN SNCA SNCAIP
2 corticobasal degeneration 32.2 GBA LRRK2 MAPT RPS27A
3 frontotemporal dementia 29.1 ACHE APOE APP LRRK2 MAPT PRNP
4 synucleinopathy 28.8 APP GBA LRRK2 MAOB MAPT PARK7
5 alzheimer disease 28.4 ACHE APOE APP BCHE MAOB MAPT
6 dementia 28.2 ACHE APOE APP BCHE GBA LRRK2
7 parkinson disease, late-onset 28.0 ACHE APOE APP BCHE CYP2D6 GBA
8 parkinson disease 1, autosomal dominant 11.9
9 parkinson disease 4, autosomal dominant 11.8
10 myoclonic epilepsy of lafora 11.1
11 hereditary late-onset parkinson disease 10.9 GBA LRRK2 SNCA
12 simultanagnosia 10.8 APOE MAPT
13 senile plaque formation 10.8 APOE APP
14 posterior cortical atrophy 10.8 APOE MAPT
15 genetic prion diseases 10.7 APOE PRNP
16 familial idiopathic basal ganglia calcification 10.7 APOE APP MAPT
17 niemann-pick disease, type c1 10.7 APP MAPT SNCA
18 akinetic mutism 10.7 MAPT PRNP SLC6A3
19 neuronal intranuclear inclusion disease 10.7 MAPT RPS27A SNCA
20 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 10.6 MAPT RPS27A
21 semantic dementia 10.6 APOE MAPT RPS27A
22 postencephalitic parkinson disease 10.6 LRRK2 MAOB MAPT SNCA
23 dysautonomia 10.6 GBA PRNP SNCA SNCAIP
24 parkinson disease 10 10.6 LRRK2 PARK7 PRKN SNCA
25 parkinson disease 2, autosomal recessive juvenile 10.6 LRRK2 PARK7 PRKN SNCA
26 essential tremor 10.6 LRRK2 PRKN SLC6A3 SNCA
27 butyrylcholinesterase deficiency 10.5 ACHE BCHE
28 neurodegeneration with brain iron accumulation 2a 10.5 APP RPS27A SNCB
29 prion disease 10.5 APP MAPT PRNP
30 alzheimer disease 2 10.5 APOE APP BCHE MAPT
31 binswanger's disease 10.5 ACHE APOE APP MAPT
32 machado-joseph disease 10.5 RPS27A SLC6A3 SNCA
33 tremor 10.5 GBA LRRK2 MAPT PRKN SNCA
34 perry syndrome 10.5 SLC18A2 SLC6A3 SNCA TH
35 hypoganglionosis 10.5 ACHE TH
36 cocaine abuse 10.5 BCHE SLC18A2 SLC6A3 SNCA
37 pure autonomic failure 10.5 ACHE MAOB SNCA TH
38 cerebral amyloid angiopathy, cst3-related 10.4 APOE APP MAPT PRNP
39 early-onset parkinson's disease 10.4 GBA LRRK2 PARK7 PRKN SNCA
40 creutzfeldt-jakob disease 10.4 APOE MAPT PRNP
41 inclusion body myositis 10.4 APOE APP MAPT RPS27A
42 agraphia 10.4 ACHE BCHE MAPT PRNP
43 pick disease of brain 10.3 APOE APP MAPT RPS27A SNCA
44 rem sleep behavior disorder 10.3 ACHE LRRK2 RPS27A SLC6A3 SNCA
45 restless legs syndrome 10.3 MAOB PRKN SLC6A3 SNCA TH
46 vascular dementia 10.3 ACHE APOE APP BCHE MAPT
47 cerebral hemorrhage 10.3 APP PRNP
48 alcohol dependence 10.3 MAOB SLC18A2 SLC6A3 SNCA
49 leukoencephalopathy, hereditary diffuse, with spheroids 10.2 APP MAPT PRNP RPS27A SNCA
50 psychotic disorder 10.2 CYP2D6 MAOB SLC18A2 SLC6A3

Graphical network of the top 20 diseases related to Dementia, Lewy Body:



Diseases related to Dementia, Lewy Body

Symptoms & Phenotypes for Dementia, Lewy Body

Symptoms via clinical synopsis from OMIM:

57
Neurologic Central Nervous System:
parkinsonism
delusions
visual hallucinations
fluctuations in consciousness
progressive dementia
more

Clinical features from OMIM:

127750

Human phenotypes related to Dementia, Lewy Body:

32
# Description HPO Frequency HPO Source Accession
1 dementia 32 HP:0000726
2 parkinsonism 32 HP:0001300
3 delusions 32 HP:0000746
4 visual hallucinations 32 HP:0002367
5 fluctuations in consciousness 32 HP:0007159

UMLS symptoms related to Dementia, Lewy Body:


back pain, headache, pain, sciatica, seizures, syncope, tremor, chronic pain, hallucinations, visual, vertigo/dizziness, sleeplessness

MGI Mouse Phenotypes related to Dementia, Lewy Body:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 ACHE APOE APP GBA LRRK2 MAOB
2 homeostasis/metabolism MP:0005376 10.36 TH ACHE APOE APP BCHE GBA
3 cellular MP:0005384 10.32 APOE APP GBA LRRK2 MAOB MAPT
4 growth/size/body region MP:0005378 10.27 SLC18A2 SLC6A3 SNCA SNCB TH APOE
5 mortality/aging MP:0010768 10.21 GBA LRRK2 MAPT PRKN PRNP SLC18A2
6 nervous system MP:0003631 10.16 GBA LRRK2 MAOB MAPT PARK7 PRKN
7 cardiovascular system MP:0005385 10.15 APOE APP GBA LRRK2 MAPT PRKN
8 integument MP:0010771 10.1 APOE APP GBA LRRK2 MAPT PRKN
9 muscle MP:0005369 9.92 ACHE APOE APP MAPT PRKN PRNP
10 no phenotypic analysis MP:0003012 9.85 SNCB TH ACHE APOE APP LRRK2
11 normal MP:0002873 9.65 APP GBA LRRK2 MAPT PRKN PRNP
12 taste/olfaction MP:0005394 9.02 MAPT SLC18A2 SLC6A3 SNCA APOE

Drugs & Therapeutics for Dementia, Lewy Body

Drugs for Dementia, Lewy Body (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 72)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Armodafinil Approved, Investigational Phase 4,Not Applicable 112111-43-0
2
Modafinil Approved, Investigational Phase 4,Not Applicable 68693-11-8 4236
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
4
Donepezil Approved Phase 4,Phase 3,Phase 2,Not Applicable 120014-06-4 3152
5
Memantine Approved, Investigational Phase 4,Phase 2 19982-08-2 4054
6
Acetaminophen Approved Phase 4 103-90-2 1983
7
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
8
Iodine Approved, Investigational Phase 4 7553-56-2 807
9
Corticosterone Experimental Phase 4 50-22-6 5753
10 Central Nervous System Stimulants Phase 4,Not Applicable
11 Cytochrome P-450 CYP3A Inducers Phase 4,Not Applicable
12 Wakefulness-Promoting Agents Phase 4,Not Applicable
13 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
15 Cholinergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Cholinesterase Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
17 Nootropic Agents Phase 4,Phase 3,Phase 2,Not Applicable
18 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Not Applicable
19 Excitatory Amino Acid Antagonists Phase 4,Phase 2
20 Excitatory Amino Acids Phase 4,Phase 2
21 Analgesics Phase 4
22 Analgesics, Non-Narcotic Phase 4
23 Analgesics, Opioid Phase 4
24 Antipyretics Phase 4
25 Central Nervous System Depressants Phase 4,Phase 3
26 Narcotic Antagonists Phase 4
27 Narcotics Phase 4
28 Peripheral Nervous System Agents Phase 4,Phase 3,Not Applicable
29 Pharmaceutical Solutions Phase 4,Not Applicable
30 cadexomer iodine Phase 4
31 Anti-Inflammatory Agents Phase 4
32 Fluorodeoxyglucose F18 Phase 4
33 Calamus Nutraceutical Phase 4
34
Galantamine Approved Phase 3 357-70-0 9651
35
Pimavanserin Approved, Investigational Phase 3 706779-91-1 16058810
36 Autonomic Agents Phase 3,Not Applicable
37 Protective Agents Phase 3,Not Applicable
38 Antipsychotic Agents Phase 3
39 Psychotropic Drugs Phase 3
40 Serotonin Agents Phase 3
41 Tranquilizing Agents Phase 3
42
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
43
Riluzole Approved, Investigational Phase 2 1744-22-5 5070
44 Dopamine agonists Phase 2,Phase 1,Not Applicable
45
Acetylcholine Approved Not Applicable 51-84-3 187
46
Rivastigmine Approved, Investigational 123441-03-2 77991
47
Acetylcysteine Approved, Investigational 616-91-1 12035
48
Dextromethorphan Approved 125-71-3 5360696 5362449
49
Hydroxocobalamin Approved 13422-51-0 11953898 44475014
50
Quinidine Approved, Investigational 56-54-2 441074

Interventional clinical trials:

(show top 50) (show all 92)
# Name Status NCT ID Phase Drugs
1 "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies" Completed NCT01023672 Phase 4 Armodafinil
2 Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies Completed NCT00855686 Phase 4 Memantine;Placebo
3 Efficacy of Pain Treatment on Depression in Patients With Dementia Completed NCT02267057 Phase 4 Paracetamol;Buprenorphine;Paracetamol placebo;Buprenorphine placebo
4 A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB) Active, not recruiting NCT02345213 Phase 4 E2020;Placebo
5 DaTSCAN Imaging in Aging and Neurodegenerative Disease Enrolling by invitation NCT01453127 Phase 4 I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)
6 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
7 Evaluating the Effects of Music Interventions on Hospitalised People With Dementia Unknown status NCT00448318 Phase 2, Phase 3
8 Donepezil Treatment of Psychotic Symptoms in Dementia Patients Unknown status NCT00190021 Phase 3 donepezil
9 A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase Completed NCT01278407 Phase 3 Donepezil 5 mg;Donepezil 10 mg;Donepezil matched placebo
10 Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies Completed NCT00230997 Phase 3 Galantamine
11 Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia Completed NCT00209456 Phase 3 DatSCAN
12 Oculomotor Testing in the Differential Diagnosis of Dementia Completed NCT01577394 Phase 3
13 Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis Recruiting NCT03325556 Phase 3 Placebo;Pimavanserin 34 mg;Pimavanserin 20 mg
14 Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension Terminated NCT02928445 Phase 2, Phase 3 RVT-101 35 mg;RVT-101 70 mg
15 Effect of Donepezil on Cognition in Parkinson's Disease With Mild Cognitive Impairment (PD-MCI) Unknown status NCT02450786 Phase 2 Donepezil
16 Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study Completed NCT02669433 Phase 2 RVT-101 35 mg;RVT-101 70 mg;Placebo
17 Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia Completed NCT02640729 Phase 2 Nelotanserin;Placebo
18 A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies Completed NCT00598650 Phase 2 E2020
19 A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431) Completed NCT00543855 Phase 2 3 mg Donepezil hydrochloride;5 mg Donepezil hydrochloride;10 mg Donepezil hydrochloride;Placebo
20 Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB) Completed NCT00630500 Phase 2 Memantine;Placebo
21 Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia Completed NCT02910102 Phase 2 RVT-101 35 mg;Placebo
22 A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET) Completed NCT01503944 Phase 1, Phase 2 18F-AV-133;18F-AV-45
23 11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes Recruiting NCT03555292 Phase 2 11C-PiB
24 Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies Active, not recruiting NCT02702102 Phase 2 11C-PBR28
25 Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD) Active, not recruiting NCT02708186 Phase 2 Nelotanserin;Placebo
26 Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder Enrolling by invitation NCT02871427 Phase 2 Nelotanserin
27 Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies Not yet recruiting NCT03467152 Phase 2 E2027;Placebo
28 A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831 Not yet recruiting NCT03538522 Phase 2 N-831(Traneurocin) 10 mg QD;NA-831 (Traneurocin) 20 mg QD;NA-831 (Traneurocin) 40 mg QD;Placebo oral capsule QD
29 Therapy in Amyotrophic Lateral Sclerosis With Memantine at 20 mg BID (TAME) Not yet recruiting NCT02118727 Phase 2 Memantine;Placebo (for Memantine)
30 Nilotinib in Cognitively Impaired Parkinson Disease Patients 001 Completed NCT02281474 Phase 1 Nilotinib
31 Alpha-synuclein in Cerebrospinal Fluid to Differentiate Alzheimer's Disease From Lewy Body Disease. Unknown status NCT01876459 Not Applicable
32 Construction-LBD (Constructional Apraxia in Alzheimer's Disease (AD) and Lewy Body's Dementia (LBD)) Unknown status NCT01993628 Not Applicable
33 Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies Unknown status NCT01256905 Not Applicable Armodafinil
34 Gait and REM Sleep Behavior Disorder Unknown status NCT02554331 Not Applicable
35 Parkinson's Disease, Diagnostic Observations (PADDO) Unknown status NCT01249768
36 Imaging of Vesicular Acetylcholine and Dopamine Transporters in Dementia With Lewy Bodies Completed NCT00917709 Not Applicable
37 Effects of Nucleus Basalis of Meynert Stimulation on Cognitive Disorders in Dementia With Lewy Bodies Completed NCT01340001 Not Applicable
38 A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease Completed NCT01944436 Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)
39 Deep Brain Stimulation for Patients With Dementia With Lewy Bodies Completed NCT02263937 Not Applicable
40 Diagnostic of Lewy Body Dementia by Combining Scintigraphy (SPECT) Using a Specific Transporter and Magnetic Resonance Imaging (MRI) Completed NCT00820937 Not Applicable
41 Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB) Completed NCT00776347 Not Applicable Donepezil;Donepezil
42 Treadmill Walking in Individuals With Dementia With Lewy Bodies and Huntington's Disease Completed NCT02268617 Not Applicable
43 A Longitudinal Multidimensional Population Study on Brain Aging Completed NCT01345110
44 Research of Biomarkers in Parkinson Disease Completed NCT00465790
45 Systematic Care for Informal Caregivers of Dementia Patients: An Efficient Approach? Completed NCT00147693 Not Applicable
46 Assessment of Social-emotional Functioning in Neurological Diseases Completed NCT01339130 Not Applicable
47 Visual Function During Gait in Parkinson's Disease: Impact of Cognition and Response to Visual Cues Completed NCT02610634
48 Predictive and Diagnostic Value of Tau and Beta-amyloid Markers in the Dementia of Parkinson's Disease Completed NCT02243982 Early Phase 1
49 Study of MRI 3Tesla Infusion Without Arterial Spin Labeling Injection (ASL) in Cognitive Atypical and Comparison to the FDG-PET Completed NCT02058043
50 Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia Completed NCT00880347 Not Applicable

Search NIH Clinical Center for Dementia, Lewy Body

Cochrane evidence based reviews: lewy body disease

Genetic Tests for Dementia, Lewy Body

Genetic tests related to Dementia, Lewy Body:

# Genetic test Affiliating Genes
1 Lewy Body Dementia 29 GBA SNCA SNCB
2 Lewy Bodies 29

Anatomical Context for Dementia, Lewy Body

MalaCards organs/tissues related to Dementia, Lewy Body:

41
Brain, Heart, Eye, Testes, Colon, Temporal Lobe, Prefrontal Cortex

Publications for Dementia, Lewy Body

Articles related to Dementia, Lewy Body:

(show top 50) (show all 162)
# Title Authors Year
1
When Post-Traumatic Stress Disorder and Charles Bonnet Syndrome Become Lewy Body Dementia. ( 29778582 )
2018
2
Clinical prevalence of Lewy body dementia. ( 29448953 )
2018
3
Dementia, Lewy Body ( 29494048 )
2018
4
ALBA Screening Instrument (ASI): A brief screening tool for Lewy Body Dementia. ( 28088604 )
2017
5
Genetic association between RAGE polymorphisms and Alzheimer's disease and Lewy body dementias in a Japanese cohort: a case-control study. ( 27699858 )
2017
6
An iTRAQ-based proteomic analysis reveals dysregulation of neocortical synaptopodin in Lewy body dementias. ( 28800743 )
2017
7
Divergent functional connectivity during attentional processing in Lewy body dementia and Alzheimer's disease. ( 28391039 )
2017
8
Neuroleptic Malignant Syndrome Caused by Quetiapine in an Elderly Man with Lewy Body Dementia. ( 27564641 )
2016
9
GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia. ( 26938614 )
2016
10
Unfolded protein response is activated in Lewy body dementias. ( 26202523 )
2016
11
Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with I^-amyloid burden and synaptic deficits in Lewy body dementias. ( 27609071 )
2016
12
Patient with rapidly evolving neurological disease with neuropathological lesions of Creutzfeldt-Jakob disease, Lewy body dementia, chronic subcortical vascular encephalopathy and meningothelial meningioma. ( 27634418 )
2016
13
Motor performance differentiates individuals with Lewy body dementia, Parkinson's and Alzheimer's disease. ( 27544062 )
2016
14
The effects of behavioral and psychological symptoms on caregiver burden in frontotemporal dementia, Lewy body dementia, and Alzheimer's disease: clinical experience in China. ( 26882509 )
2016
15
Somatoform and Conversion Disorder Preceding Lewy Body Dementia: A Newly Described Phenomenological Manifestation of the Disease. ( 26390000 )
2015
16
Cognitive fluctuations in connection to dysgraphia: a comparison of Alzheimer's disease with dementia Lewy bodies. ( 25848239 )
2015
17
The possible involvement of mitochondrial dysfunctions in Lewy body dementia: a systematic review. ( 26346695 )
2015
18
The cholinergic basal forebrain in Lewy body dementia and Alzheimer's disease. ( 25504308 )
2015
19
Function of I+-synuclein and PINK1 in Lewy body dementia (Review). ( 25355138 )
2014
20
Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia. ( 25671083 )
2014
21
Long-term mortality in a cohort of home-dwelling elderly with mild Alzheimer's disease and Lewy body dementia. ( 24732348 )
2014
22
Cortical changes associated with depression and antidepressant use in Alzheimer and Lewy body dementia: an MRI surface-based morphometric study. ( 23880336 )
2014
23
Determining the association of the 5HTTLPR polymorphism with delusions and hallucinations in Lewy body dementias. ( 23582751 )
2014
24
Late-onset Bing-Neel syndrome associated with delirium and Lewy body dementia. ( 25413203 )
2014
25
18F-FDG PET Assessment of Lewy Body Dementia with Cerebellar Diaschisis. ( 25190733 )
2014
26
Topiramate improves psychiatric symptoms in a patient with Lewy body dementia. ( 25539042 )
2014
27
Capgras-like visual decomposition in Lewy body dementia with therapeutic response to donepezil. ( 25566416 )
2014
28
Nature and extent of person recognition impairments associated with Capgras syndrome in Lewy body dementia. ( 25309399 )
2014
29
Lewy body dementia: the impact on patients and caregivers. ( 25031635 )
2014
30
Understanding Lewy body dementia. ( 24937845 )
2014
31
Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment. ( 25104558 )
2014
32
Sequence variants in eukaryotic translation initiation factor 4-gamma (eIF4G1) are associated with Lewy body dementia. ( 23124435 )
2013
33
Determination of the biodistribution and dosimetry of A^A^A^I-FP-CIT in male patients with suspected Parkinsonism or Lewy body dementia using planar and combined planar and SPECT/CT imaging. ( 24135637 )
2013
34
Dysphagia in Lewy body dementia - a clinical observational study of swallowing function by videofluoroscopic examination. ( 24099488 )
2013
35
Intrusion of rapid eye movement (REM) behavior disorder episodes into NREM sleep in a case of Lewy body dementia. ( 23063303 )
2013
36
Lewy Body Dementia: The Under-Recognized but Common FOE. ( 24772233 )
2013
37
An effective environmental intervention for management of the 'mirror sign' in a case of probable Lewy body dementia. ( 22229711 )
2013
38
Sympathetic skin response and heart rate variability as diagnostic tools for the differential diagnosis of Lewy body dementia and Alzheimer's disease: a diagnostic test study. ( 23457321 )
2013
39
[Utility of early imaging of myocardial innervation scintigraphy in the diagnosis of Lewy Body Dementia]. ( 23177334 )
2013
40
Word list and story recall elicit different patterns of memory deficit in patients with Alzheimer's disease, frontotemporal dementia, subcortical ischemic vascular disease, and Lewy body dementia. ( 23792693 )
2013
41
Dysphagia due to isoniazid therapy for tuberculosis in a patient with Lewy body dementia. ( 22608343 )
2013
42
Visual hallucinations treated with the reinitiation of memantine in a patient with Lewy body dementia. ( 23386073 )
2013
43
Prevalence of cerebrovascular lesions in patients with Lewy body dementia: a neuropathological study. ( 23237637 )
2013
44
Neuropsychological Correlates of Behavioral Symptoms in Alzheimer's Disease, Frontal Variant of Frontotemporal, Subcortical Vascular, and Lewy Body Dementias: A Comparative Study. ( 24254701 )
2013
45
Neuropathological correlates of volumetric MRI in autopsy-confirmed Lewy body dementia. ( 21353336 )
2012
46
The "closing-in" phenomenon in Parkinson's disease dementia and lewy-body dementia. ( 23224479 )
2012
47
The high frequency of periodic limb movements in patients with Lewy body dementia. ( 22835911 )
2012
48
Decreased oligodendrocyte nuclear diameter in Alzheimer's disease and Lewy body dementia. ( 22429607 )
2012
49
No association of COMT val158met polymorphism and psychotic symptoms in Lewy body dementias. ( 23069674 )
2012
50
White matter hyperintensities in mild lewy body dementia. ( 23189084 )
2012

Variations for Dementia, Lewy Body

UniProtKB/Swiss-Prot genetic disease variations for Dementia, Lewy Body:

75
# Symbol AA change Variation ID SNP ID
1 SNCA p.Glu46Lys VAR_022703 rs104893875

ClinVar genetic disease variations for Dementia, Lewy Body:

6
(show all 17)
# Gene Variation Type Significance SNP ID Assembly Location
1 GBA NM_000157.3(GBA): c.1448T> C (p.Leu483Pro) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs421016 GRCh37 Chromosome 1, 155205043: 155205043
2 GBA NM_000157.3(GBA): c.1448T> C (p.Leu483Pro) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs421016 GRCh38 Chromosome 1, 155235252: 155235252
3 GBA NM_001005741.2(GBA): c.1226A> G (p.Asn409Ser) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs76763715 GRCh37 Chromosome 1, 155205634: 155205634
4 GBA NM_001005741.2(GBA): c.1226A> G (p.Asn409Ser) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs76763715 GRCh38 Chromosome 1, 155235843: 155235843
5 SNCB NM_001001502.2(SNCB): c.208G> A (p.Val70Met) single nucleotide variant Pathogenic rs104893936 GRCh37 Chromosome 5, 176053473: 176053473
6 SNCB NM_001001502.2(SNCB): c.208G> A (p.Val70Met) single nucleotide variant Pathogenic rs104893936 GRCh38 Chromosome 5, 176626472: 176626472
7 SNCB NM_001001502.2(SNCB): c.368C> A (p.Pro123His) single nucleotide variant Pathogenic rs104893937 GRCh37 Chromosome 5, 176048219: 176048219
8 SNCB NM_001001502.2(SNCB): c.368C> A (p.Pro123His) single nucleotide variant Pathogenic rs104893937 GRCh38 Chromosome 5, 176621218: 176621218
9 SNCA NM_000345.3(SNCA): c.136G> A (p.Glu46Lys) single nucleotide variant Pathogenic rs104893875 GRCh37 Chromosome 4, 90749321: 90749321
10 SNCA NM_000345.3(SNCA): c.157G> A (p.Ala53Thr) single nucleotide variant Pathogenic rs104893877 GRCh37 Chromosome 4, 90749300: 90749300
11 SNCA NM_000345.3(SNCA): c.157G> A (p.Ala53Thr) single nucleotide variant Pathogenic rs104893877 GRCh38 Chromosome 4, 89828149: 89828149
12 SNCA NM_000345.3(SNCA): c.136G> A (p.Glu46Lys) single nucleotide variant Pathogenic rs104893875 GRCh38 Chromosome 4, 89828170: 89828170
13 SNCA SNCA, DUPLICATION duplication Pathogenic
14 SNCA NM_000345.3(SNCA): c.408C> T (p.Tyr136=) single nucleotide variant Benign/Likely benign rs76642636 GRCh38 Chromosome 4, 89726643: 89726643
15 SNCA NM_000345.3(SNCA): c.408C> T (p.Tyr136=) single nucleotide variant Benign/Likely benign rs76642636 GRCh37 Chromosome 4, 90647794: 90647794
16 SNCA NC_000004.12: g.(?_89726164)_(89835687_?)dup duplication Pathogenic GRCh38 Chromosome 4, 89726164: 89835687
17 SNCA NC_000004.12: g.(?_89726164)_(89835687_?)dup duplication Pathogenic GRCh37 Chromosome 4, 90647315: 90756838

Expression for Dementia, Lewy Body

Search GEO for disease gene expression data for Dementia, Lewy Body.

Pathways for Dementia, Lewy Body

Pathways related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.64 APP MAOB PRKN RPS27A SLC18A2 SLC6A3
2
Show member pathways
13.25 APOE APP LRRK2 MAPT PARK7 PRKN
3
Show member pathways
12.53 PARK7 PRKN SLC6A3 SNCA SNCAIP
4 11.9 APOE APP LRRK2 MAPT PARK7 PRKN
5
Show member pathways
11.8 MAOB SLC18A2 SLC6A3 TH
6 11.72 APP CYP2D6 MAOB SLC18A2
7 11.62 LRRK2 PARK7 PRKN SLC6A3 SNCA SNCAIP
8 11.42 APP MAPT PRNP
9 11.32 APOE APP MAPT
10
Show member pathways
11.29 ACHE SLC6A3 TH
11 11.2 ACHE APOE CYP2D6
12 11.06 SLC18A2 SLC6A3 TH
13 10.94 MAOB PARK7 PRKN SLC6A3 SNCA TH
14
Show member pathways
10.91 ACHE BCHE SLC6A3
15 10.7 MAOB TH
16 10.63 PRKN RPS27A
17 10.62 ACHE TH

GO Terms for Dementia, Lewy Body

Cellular components related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.99 ACHE APP LRRK2 SNCA SNCB
2 perinuclear region of cytoplasm GO:0048471 9.97 ACHE APP PARK7 PRKN SNCA SNCG
3 dendrite GO:0030425 9.95 APOE LRRK2 MAPT PRNP TH
4 neuron projection GO:0043005 9.87 APP LRRK2 MAPT PARK7 PRKN SLC6A3
5 mitochondrial outer membrane GO:0005741 9.83 LRRK2 MAOB RPS27A SNCA
6 membrane raft GO:0045121 9.8 APP LRRK2 PARK7 PRNP SLC6A3
7 synaptic vesicle GO:0008021 9.77 LRRK2 SLC18A2 SNCA SNCAIP TH
8 growth cone GO:0030426 9.76 APP LRRK2 MAPT SNCA
9 presynapse GO:0098793 9.74 PARK7 PRKN SLC6A3
10 postsynapse GO:0098794 9.71 LRRK2 PRNP SNCA
11 terminal bouton GO:0043195 9.65 APP LRRK2 SLC18A2 SNCA TH
12 amyloid-beta complex GO:0106003 9.6 APOE PRNP
13 nuclear envelope lumen GO:0005641 9.56 APP BCHE
14 neuronal cell body GO:0043025 9.56 APOE LRRK2 MAPT SLC6A3 SNCA SNCAIP
15 main axon GO:0044304 9.51 APP MAPT
16 inclusion body GO:0016234 9.46 LRRK2 PRNP SNCA SNCB
17 axon GO:0030424 9.23 APP LRRK2 MAPT PARK7 SLC6A3 SNCA
18 membrane GO:0016020 10.49 ACHE APOE APP BCHE CYP2D6 GBA
19 cytoplasm GO:0005737 10.35 APOE APP CYP2D6 LRRK2 MAPT PARK7
20 extracellular space GO:0005615 10.19 ACHE APOE APP BCHE GBA LRRK2
21 endoplasmic reticulum GO:0005783 10.15 APOE BCHE CYP2D6 LRRK2 PARK7 PRKN
22 Golgi apparatus GO:0005794 10.12 ACHE APOE APP LRRK2 PRKN PRNP
23 mitochondrion GO:0005739 10.09 CYP2D6 LRRK2 MAOB MAPT PARK7 PRKN

Biological processes related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.99 APOE APP MAPT PARK7 PRKN
2 cellular protein metabolic process GO:0044267 9.95 APOE APP PRKN RPS27A SNCA SNCAIP
3 negative regulation of neuron apoptotic process GO:0043524 9.93 APOE PARK7 PRKN SNCA SNCB
4 response to oxidative stress GO:0006979 9.92 APOE APP LRRK2 PRKN PRNP
5 cellular response to oxidative stress GO:0034599 9.9 LRRK2 PARK7 SNCA
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.9 APP PARK7 SNCA
7 mitochondrion organization GO:0007005 9.9 GBA LRRK2 PARK7 PRKN
8 positive regulation of proteasomal ubiquitin-dependent protein catabolic process GO:0032436 9.88 GBA LRRK2 PRKN
9 regulation of autophagy GO:0010506 9.87 LRRK2 MAPT PRKN
10 learning GO:0007612 9.87 APP BCHE PRKN TH
11 positive regulation of protein binding GO:0032092 9.85 APP LRRK2 PRKN
12 locomotory behavior GO:0007626 9.85 APP PRKN SLC18A2 SLC6A3 TH
13 negative regulation of protein phosphorylation GO:0001933 9.83 LRRK2 PARK7 PRKN PRNP SNCA
14 protein destabilization GO:0031648 9.82 PRKN PRNP SNCA
15 positive regulation of neuron death GO:1901216 9.79 MAPT PRNP SNCA
16 regulation of dopamine secretion GO:0014059 9.76 PRKN SNCA SNCG
17 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.75 LRRK2 PARK7 PRKN
18 regulation of peptidyl-tyrosine phosphorylation GO:0050730 9.74 APP PRNP
19 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.74 LRRK2 PARK7
20 cellular copper ion homeostasis GO:0006878 9.74 APP PRNP
21 response to corticosterone GO:0051412 9.74 MAOB TH
22 microglial cell activation GO:0001774 9.73 MAPT SNCA
23 cellular response to dopamine GO:1903351 9.73 LRRK2 PRKN
24 locomotory exploration behavior GO:0035641 9.73 APOE LRRK2
25 supramolecular fiber organization GO:0097435 9.73 MAPT SNCA
26 neurotransmitter biosynthetic process GO:0042136 9.73 ACHE SLC6A3 TH
27 negative regulation of protein processing GO:0010955 9.72 LRRK2 PRNP
28 regulation of protein metabolic process GO:0051246 9.72 APOE GBA
29 amyloid precursor protein metabolic process GO:0042982 9.72 ACHE APOE
30 virion assembly GO:0019068 9.72 APOE RPS27A
31 dopamine biosynthetic process GO:0042416 9.72 SLC6A3 SNCA TH
32 adult locomotory behavior GO:0008344 9.72 APP PARK7 PRKN SNCA SNCG
33 neurotransmitter catabolic process GO:0042135 9.71 ACHE MAOB
34 negative regulation of reactive oxygen species biosynthetic process GO:1903427 9.71 PARK7 SLC18A2
35 regulation of dopamine metabolic process GO:0042053 9.71 PRKN SLC6A3
36 positive regulation of protein metabolic process GO:0051247 9.71 APP GBA
37 regulation of neurotransmitter secretion GO:0046928 9.71 PRKN SNCA SNCAIP SNCG
38 amyloid fibril formation GO:1990000 9.7 APP MAPT
39 monoamine transport GO:0015844 9.7 SLC18A2 SLC6A3
40 negative regulation of amyloid-beta formation GO:1902430 9.7 APOE PRNP
41 dopamine catabolic process GO:0042420 9.69 MAOB SLC6A3
42 astrocyte activation GO:0048143 9.69 APP MAPT
43 mating behavior GO:0007617 9.69 APP TH
44 negative regulation of long-term synaptic potentiation GO:1900272 9.69 APOE APP PRNP
45 intracellular distribution of mitochondria GO:0048312 9.68 LRRK2 MAPT
46 regulation of mitochondrial fission GO:0090140 9.68 LRRK2 MAPT
47 regulation of locomotion GO:0040012 9.68 LRRK2 SNCA
48 modulation of age-related behavioral decline GO:0090647 9.67 APP PRNP
49 positive regulation of microglial cell activation GO:1903980 9.67 APP LRRK2
50 dopamine transport GO:0015872 9.67 SLC18A2 SLC6A3

Molecular functions related to Dementia, Lewy Body according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.99 ACHE APOE LRRK2 MAOB MAPT PARK7
2 microtubule binding GO:0008017 9.83 LRRK2 MAPT PRNP SNCA
3 chaperone binding GO:0051087 9.73 MAPT PRKN PRNP
4 enzyme binding GO:0019899 9.7 APP BCHE MAPT PARK7 PRKN SNCA
5 copper ion binding GO:0005507 9.65 PARK7 PRNP SNCA
6 identical protein binding GO:0042802 9.65 APOE APP BCHE LRRK2 MAPT PARK7
7 amyloid-beta binding GO:0001540 9.62 ACHE APOE BCHE PRNP
8 tau protein binding GO:0048156 9.58 APOE SNCA
9 ubiquitin-specific protease binding GO:1990381 9.57 PARK7 PRKN
10 tubulin binding GO:0015631 9.56 LRRK2 MAPT PRKN PRNP
11 phospholipase binding GO:0043274 9.55 PRKN SNCA
12 dopamine binding GO:0035240 9.54 SLC6A3 TH
13 monoamine transmembrane transporter activity GO:0008504 9.49 SLC18A2 SLC6A3
14 lipoprotein particle binding GO:0071813 9.46 APOE MAPT
15 cholinesterase activity GO:0004104 9.43 ACHE BCHE
16 cupric ion binding GO:1903135 9.4 PARK7 PRNP
17 acetylcholinesterase activity GO:0003990 9.37 ACHE BCHE
18 cuprous ion binding GO:1903136 8.92 PARK7 PRNP SNCA SNCB

Sources for Dementia, Lewy Body

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....